Anika Therapeutics (ANIK) Competitors $9.38 +0.15 (+1.63%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.40 +0.01 (+0.16%) As of 08/29/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANIK vs. ANVS, CERS, OSUR, UTMD, WST, COO, ALGN, MMSI, ICUI, and XRAYShould you be buying Anika Therapeutics stock or one of its competitors? The main competitors of Anika Therapeutics include Annovis Bio (ANVS), Cerus (CERS), OraSure Technologies (OSUR), Utah Medical Products (UTMD), West Pharmaceutical Services (WST), Cooper Companies (COO), Align Technology (ALGN), Merit Medical Systems (MMSI), ICU Medical (ICUI), and DENTSPLY SIRONA (XRAY). These companies are all part of the "medical" sector. Anika Therapeutics vs. Its Competitors Annovis Bio Cerus OraSure Technologies Utah Medical Products West Pharmaceutical Services Cooper Companies Align Technology Merit Medical Systems ICU Medical DENTSPLY SIRONA Anika Therapeutics (NASDAQ:ANIK) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk. Do analysts recommend ANIK or ANVS? Anika Therapeutics presently has a consensus target price of $18.00, suggesting a potential upside of 91.90%. Annovis Bio has a consensus target price of $18.00, suggesting a potential upside of 675.86%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than Anika Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anika Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Do insiders & institutionals hold more shares of ANIK or ANVS? 91.5% of Anika Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 9.6% of Anika Therapeutics shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, ANIK or ANVS? Anika Therapeutics has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.65, indicating that its stock price is 65% more volatile than the S&P 500. Is ANIK or ANVS more profitable? Annovis Bio has a net margin of 0.00% compared to Anika Therapeutics' net margin of -48.99%. Anika Therapeutics' return on equity of -10.97% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Anika Therapeutics-48.99% -10.97% -8.51% Annovis Bio N/A -206.01%-158.26% Does the media prefer ANIK or ANVS? In the previous week, Anika Therapeutics had 4 more articles in the media than Annovis Bio. MarketBeat recorded 4 mentions for Anika Therapeutics and 0 mentions for Annovis Bio. Anika Therapeutics' average media sentiment score of 0.64 beat Annovis Bio's score of 0.00 indicating that Anika Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Anika Therapeutics Positive Annovis Bio Neutral Which has stronger earnings and valuation, ANIK or ANVS? Annovis Bio has lower revenue, but higher earnings than Anika Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnika Therapeutics$119.91M1.13-$56.38M-$4.15-2.26Annovis BioN/AN/A-$24.59M-$2.04-1.14 SummaryAnika Therapeutics and Annovis Bio tied by winning 8 of the 16 factors compared between the two stocks. Get Anika Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIK vs. The Competition Export to ExcelMetricAnika TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$135.26M$3.08B$5.69B$9.74BDividend YieldN/A2.28%6.64%4.48%P/E Ratio-2.2620.9283.1926.59Price / Sales1.13352.35515.16159.07Price / Cash98.3443.5325.6628.92Price / Book0.899.7811.766.08Net Income-$56.38M-$54.01M$3.27B$265.93M7 Day Performance2.74%0.10%1.13%0.36%1 Month Performance8.56%8.52%8.30%5.58%1 Year Performance-63.50%7.03%62.26%19.67% Anika Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIKAnika Therapeutics4.2894 of 5 stars$9.38+1.6%$18.00+91.9%-63.5%$135.26M$119.91M-2.26300ANVSAnnovis Bio1.8919 of 5 stars$2.24-5.5%$18.00+703.6%-72.6%$46.18MN/A-1.103CERSCerus2.8775 of 5 stars$1.28+1.2%$3.50+173.4%-42.0%$242.50M$180.27M-12.80290Positive NewsOSUROraSure Technologies1.8992 of 5 stars$3.14+4.7%$3.00-4.5%-26.1%$219.41M$138.53M-4.69840High Trading VolumeUTMDUtah Medical Products2.6519 of 5 stars$60.34-1.0%N/A-8.5%$195.37M$40.90M16.13180WSTWest Pharmaceutical Services4.8731 of 5 stars$246.98-0.4%$320.71+29.9%-21.2%$17.82B$2.89B36.9710,600Positive NewsCOOCooper Companies4.285 of 5 stars$73.48-2.3%$96.73+31.6%-36.3%$15.04B$3.90B35.6716,000Earnings ReportALGNAlign Technology4.9324 of 5 stars$144.96-3.1%$215.00+48.3%-40.2%$10.84B$4.00B24.4520,945Positive NewsMMSIMerit Medical Systems4.7248 of 5 stars$88.16-1.4%$107.00+21.4%-6.4%$5.30B$1.36B44.757,400Positive NewsICUIICU Medical4.6354 of 5 stars$125.81-1.8%$179.00+42.3%-22.8%$3.16B$2.38B-82.7715,000Positive NewsXRAYDENTSPLY SIRONA4.9878 of 5 stars$14.40-1.8%$18.64+29.4%-43.5%$2.92B$3.79B-3.0414,000Analyst Revision Related Companies and Tools Related Companies Annovis Bio Alternatives Cerus Alternatives OraSure Technologies Alternatives Utah Medical Products Alternatives West Pharmaceutical Services Alternatives Cooper Companies Alternatives Align Technology Alternatives Merit Medical Systems Alternatives ICU Medical Alternatives DENTSPLY SIRONA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIK) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
